Analysis-Weight-loss Drug Forecasts Jump to $150 Billion as Supply Grows
As millions seek access to weight-loss drugs from Novo Nordisk and Eli Lilly, increasing supplies, possible wider usage and a growing number of would-be rivals are leading...
Stay updated with breaking news from Patrick Wingrove. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
As millions seek access to weight-loss drugs from Novo Nordisk and Eli Lilly, increasing supplies, possible wider usage and a growing number of would-be rivals are leading...
(Reuters) -Moderna on Thursday reported quarterly revenue that beat Wall Street estimates but came in dramatically lower than the previous year when demand for COVID-19 vaccines was higher. Sales of Moderna’s COVID-19 shot Spikevax, its only marketed product, dropped 91% from the previous year to $167 million for the quarter but surpassed analysts’ expectations of $97.5 million. The Cambridge, Massachusetts-based company reaffirmed that it expects to receive approval from regulators for its resp
(Reuters) -Moderna on Thursday reported quarterly revenue that beat Wall Street estimates but came in dramatically lower than the previous year when demand for COVID-19 vaccines was higher. Sales of Moderna’s COVID-19 shot Spikevax, its only marketed product, dropped 91% from the previous year to $167 million for the quarter but surpassed analysts’ expectations of $97.5 million. The Cambridge, Massachusetts-based company reaffirmed that it expects to receive approval from regulators for its respiratory syncytial virus (RSV) vaccine in time for it to be included in this fall...
Sky-rocketing demand for Mounjaro and Zepbound, both chemically known as tirzepatide, has propelled the drugmaker's market value above $700 billion - surpassing both Tesla and Walmart. Lilly said its raised forecast reflects "greater clarity about the company's production expansion for the remainder of the year". In the short- to mid-term, the U.S. drugmaker expects sales growth for its weight-loss and diabetes treatments to primarily depend on how much it can produce and ship.
Eli Lilly beat Wall Street estimates for first-quarter profit on Tuesday, helped by rising demand for its weight-loss treatment Zepbound and type 2 diabetes drug Mounjaro. The...